

# Aspirin and the Salicylates

K. D. Rainsford, PhD, MRCPath

04377  
R971.1  
E25

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, including photocopying and recording, without the written permission of the copyright holder, application for which should be addressed to the Publisher. Such written permission must also be obtained before any part of this publication is stored in a retrieval system or any name.

This book is sold subject to the Standard Conditions of Sale of Net Books and may not be resold in the UK below the net price given by the Publisher in their current price list.

First published 1984

© Butterworth & Co. (Publishers) Ltd., 1984

# Aspirin and the Salicylates

**K. D. Rainsford, PhD, MRCPath**

Senior Research Associate

Department of Pharmacology, University of Cambridge, Cambridge


Honorary Lecturer in Chemical Pathology

King's College Hospital Medical School,

University of London, Denmark Hill, London

Visiting Reader in Pharmacology

Department of Biochemistry, University of Surrey, Guildford



**Butterworths**

London Boston Durban Singapore Sydney Toronto Wellington

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, including photocopying and recording, without the written permission of the copyright holder, application for which should be addressed to the Publishers. Such writer permission must also be obtained before any part of this publication is stored in a retrieval system of any nature.

This book is sold subject to the Standard Conditions of Sale of Net Books and may not be re-sold in the UK below the net price given by the Publisher in their current price list.

First published 1984

© Butterworth & Co. (Publishers) Ltd., 1984

**British Library Cataloguing in Publication Data**

Rainsford, Kim D.

Aspirin and the salicylates.

1. Aspirin

I. Title

615'.783

RM666.A2

ISBN 0-407-00316-9

**Library of Congress Cataloging in Publication Data**

Rainsford, K. D., 1941-

Aspirin and the salicylates.

Bibliography: p.

Includes index.

1. Salicylates. 2. Aspirin. I. Title. [DNLM:

1. Aspirin. 2. Salicylates. QV 95 R158a]

RM666.S165R34 1984

615'.783

83-15165

ISBN 0-407-00316-9

## Foreword 1

Where would we be without the salicylates? These convenient-to-use drugs, so freely available for self-medication — even by those who shun the products of the pharmaceutical manufacturers and prefer to use salves, intinctions and other herbal extracts — have been almost indispensable aids to living amongst the literate world for at least two millenia, wherever the fear of pain, the malaise of an infection and restricted movement of joints or muscles were not accepted fatalistically as being beyond relief. That life is so tolerable for so many for much of their allotted timespan is largely because of that bottle of aspirin in the family's medicine cabinet, to tide them over the next bout of toothache, muscular sprain or the 'flu.

The sheer tonnage of aspirin consumed each day and the number of its formulations in the market place are indeed remarkable statistics. Couple this with the widespread use of other salicylates as flavourants, preservatives, 'rub-on' medications etc. and we really see how indispensable this family of drugs and natural products have become for our modern way of life. Yet here, as in several other contexts, to be newer is not necessarily to be better. Drugs promoted as successors to aspirin have never really displaced it in popular acceptance. We are rediscovering some of the virtues of the less gastroirritant salicylates favoured by our forefathers before aspirin became an article of commerce. We are even told in the newspapers that cheap plain aspirin has desirable properties in controlling some forms of diarrhoea, diminishing the risk of thromboembolisms or preventing sickle-cell crises, that place this humdrum drug in the forefront of modern preventive medicine — holding a place in competition with many far more expensive, less safe, prescription-only proprietary drugs.

With this almost overwhelming popular interest in aspirin, it is still amazing how little interest has been shown in this drug by professional pharmacologists (be they biochemical, clinical, neurochemical or otherwise). I well remember the dismay I felt when I wanted to know the structure-action relationships for one of the outstanding biochemical properties of its principal metabolite, the salicylate anion. An answer to this question, I thought, required a couple of hours or so in the library looking up the classical texts or review journals in pharmacology. I ended up by having to purchase many, beg several and synthesize not a few more, chemical variants of this very simple aromatic acid and then test 80 or more of these congeners before I could begin to answer my own question. That was less than 20 years ago. Even 10 years ago, I was still being allotted only 50 minutes to lecture on aspirin and all the non-steroid anti-inflammatory/anti-pyretic/uricosuric drugs together with the treatment of salicylate

overdosage, in a well-established course in modern pharmacology (supported by its own textbook) in an otherwise very enlightened American Medical School. [The brevity of this consideration of non-prescription aspirin and all its successor prescription drugs at that time was further emphasized by including three lectures devoted to gallamine and strychnine, agents hardly encountered in a clinical context!] Fortunately, the academic 'respectability' conferred upon aspirin a decade ago, as a tool to probe the involvement of prostaglandins in many regulatory processes (then commanding the attention of experimental physiologists) has now 'washed over' into investigations of its efficacy, toxicity and clinical interactions with other drugs.

Research on the properties of salicylates manifest in different clinical contexts today proceeds at such a pace that we are now being threatened with another form of ignorance — this time as to what is in the literature, there being so much of it — as this volume amply testifies. This book is a timely and worthy successor to those classic reviews of the salicylates by Gross and Greenberg (1949) and the two Smiths (1966), and faithfully reflects the division of interest among different areas of research activity embracing aspirin and the alternative salicylates. That the coverage of some aspects may seem disproportionate *vis-à-vis* others is a strength of this great work in honestly reflecting the *status quo* concerning our wisdom and ignorance as it embraces these long-tried, but perhaps still undervalued, drugs. Matters requiring further investigation are alluded to continually. Critical insights are provided which elevate this book well above a literature compendium; but for even providing that alone, we shall all long be indebted to the author.

An old Chinese proverb says 'Without going out of the door, one can know the whole world.' Certainly this book, which is principally about aspirin, affords considerable enlightenment about topics as diverse as analytical chemistry and paediatric medicine, taxonomy and cartels, enzymology and toxicity, renal functions and rheumatology, to merely name a few. Neglected areas are brought into focus. All that we needed to know about such daunting topics as the many pathways of arachidonate transformations or the complexities of gastric proton secretions are thoughtfully provided herein to illuminate the principal topic under consideration, namely the efficacy and safety of salicylates as always with a promising future, as well as a distinguished record in history, for ameliorating so many of our ailments. *Floreat Salicylatia*.

Michael Whitehouse  
Rheumatology Research Group,  
University of Adelaide and  
Flinders University,  
Adelaide, South Australia 5001,  
Australia

## Foreword 2

The resilience of aspirin, both as a domestic remedy and a serious drug, evokes mixed feelings amongst scientists and clinicians. There are its detractors who alternately deride it as a weak non-specific pain-reliever and condemn it as a dangerous toxin causing widespread, if low grade, gastrointestinal bleeding and, on occasion, frightening attacks of bronchial asthma. In the middle range are the untold millions of lay people who take it for mild headaches and as an antipyretic and the clinicians who prescribe it as an effective and often first line anti-inflammatory agent in conditions such as active rheumatoid arthritis.

At the other end of the spectrum are the aspirinophiles. Sometimes these are research workers who have used aspirin as a test material in a laboratory system and have been intrigued by the variety and complexity of its effects on biological systems. They are seduced to explore both its history and literature and quite soon become addicted. One of the cardinal signs of such a condition is the production of a monograph on aspirin and its chemical relatives. It is no surprise to see this has now occurred with Kim Rainsford since he has already contributed many useful and original observations to the aspirin story.

Nevertheless it is a pleasure to welcome a work of real scholarship showing an enviable capacity to make sound and critical judgements in a frequently contradictory and confusing welter of facts and opinions. It is made clear that there is much more to the salicylate group of drugs, than aspirin itself. In particular, those aspects of its action, which depend on its ability to acylate biomolecules by non-enzymatic reactions, are recognized and distinguished as being confined to acetylsalicylate. This leads to a consideration of successful and effective drugs recently developed from salicylate, rather than from aspirin.

The main themes of the book are that salicylates are polycompetent drugs in that they influence a large number and variety of biological processes. Their multifactorial actions, in relation to the known therapeutic and toxic effects are clearly described. Secondly, there is a refreshing multidisciplinary approach to the subject covering the whole gamut from chemical to clinical aspects. Finally, the author is very conscious of the pathological basis of disease processes and the effects of these processes on drug metabolism and actions. In short, it is a careful stimulating and up-to-date account of this fascinating and ancient family of drugs written by a discriminating enthusiast.

M. J. H. Smith



# Preface

The salicylates are a fascinating group of drugs. Despite their apparent chemical simplicity, they have an immense array of therapeutic properties. We are also now just discovering that they have many exciting new applications.

My interest in this group started some 16 years ago when I went to London to do my PhD with Professor Mervyn Smith on the gastric mucosal reactions to the salicylates. In one sense this may have been regarded as a negative introduction to the salicylates, for by analysing the side-effects of a drug one can all too readily become somewhat engrossed in these aspects and develop a feeling that the drugs have nothing more than untoward effects with little therapeutic value by comparison. I soon learned that this was not the case with the salicylates — in fact they are a remarkably safe group of therapeutic agents. We are, however, faced today with a numerically greater number of reports of side-effects of the salicylates relative to those of other drugs, simply because they are the oldest of the anti-inflammatory/analgesic drugs and so, on statistical grounds, would be expected to have received more attention than some of the newer agents.

It was through Professor Smith's experience that I soon saw the immense diversity of actions of these drugs and also gained biochemical insight into their modes of actions. I quickly learned from my own experiments that the organs of the body respond to these drugs in many diverse ways. They present a true intellectual challenge, for in studying the actions of these drugs one has to know the intricacies of the physiological, cellular and molecular organizations one is working with to see how the drug perturbs the complexities of these systems. Moreover, the most important thing to remember is that, as with all drugs, the salicylates are employed to treat pathological conditions and so it is imperative to know what molecular and cellular events are occurring in the pathological states to appreciate how the drug influences these processes. Regrettably most of the literature on the actions of the salicylates is from studies performed in normal animals, tissues or even man. We must often, of necessity, make extrapolations and await the experiments in the particular pathological state we are anxious to treat. Unfortunately, these kinds of experiments are becoming increasingly difficult to perform with concern over both animal and human experimentation. This book is an attempt to bring together diverse concepts about the actions of the salicylates and also their therapeutic developments and applications. In one way, this may help in bringing together a very diverse array of literature and experiences of previous investigators. We

need a basis to develop newer concepts for testing to make the best use of our knowledge and benefit by new applications of different members of these drugs, especially to improve their safety.

This book would not have been possible had it not been for the help and encouragement of people to whom I would like to express special gratitude. First, Mrs Veronica Rainsford-Koechli who typed practically all the manuscript drafts, helped in faithfully translating many German and French papers and provided immense encouragement. My colleague and friend, Dr Michael Whitehouse who, from close association over the past decade, has been an immense stimulus to me in my understanding of the anti-inflammatory drugs and their actions in inflammatory states. He and Dr Brian Hasleman of Addenbrookes Hospital Cambridge also critically reviewed the manuscript in detail. Professor Mervyn Smith and other colleagues, among them Dr Bill Dawson and colleagues at the Lilly Research Centre Ltd, and also those at King's College Hospital Medical School London, Professor Kay Brune and colleagues at the Biozentrum of the University of Basel and Dr Lyndsay McLeod of the University of Tasmania, provided immense stimulation and support in my research work and understanding of the actions of salicylates and other anti-inflammatory drugs.

This book is in appreciation to these people for their help over the years.

Kim Rainsford  
Department of Pharmacology  
University of Cambridge  
Cambridge, England



# Abbreviations and Nomenclature

The term 'Aspirin' is used in accordance with its widespread generic use throughout the world as the name for the chemical, acetylsalicylic acid. In some European countries this name is still protected by Trademark (to Bayer AG). Its use in this book recognizes its convenience and widespread use in the scientific and medical community, and is in no way intended to denote use of the Trademark.

'Salicylates' is used to denote all drugs having the 2-hydroxybenzoic acid structure. When used in a general sense, it implies that, based on the current state of knowledge, it seems reasonable to employ this name to cover actions or properties of all these compounds.

Caution should, however, be expressed in such an extrapolation and the reader should be mindful of this. Standard chemical, biochemical and pharmacological abbreviations are employed and where necessary are defined where first used in the text.

Standard abbreviations are defined when first introduced in the text and have, where possible, been derived from those detailed in *Units, Symbols and Abbreviations* (1979) Ed. D. N. Baron, Royal Society of Medicine, 1 Wimpole St., London W1M 8AE.

The enzyme nomenclature employed is that described in *Enzyme Nomenclature: Recommendation of the Nomenclature Committee of the International Union of Biochemistry* (1978), Academic Press, New York, with the exception that the word 'synthetase' is employed instead of 'synthase' in accordance with common usage.

The following list of abbreviations is provided for convenient usage:

A23187 = calcium ionophore (Lilly) (= calimycin)

acetyl-SCoA = acetyl-(S)coenzyme A

ADP = adenosine diphosphate

AMP = adenosine monophosphate

Ang = angiotensin

ASA = aspirin (2-acetoxybenzoic acid = acetylsalicylic acid)

ATP = adenosine triphosphate

AUC = area under the plasma concentration curve

B-cell = bone-marrow-derived lymphocytes

BW = 755c = 3-amino-1-[*m*-(trifluoromethyl)phenyl]-2-pyrazoline

CuDIPS = copper 3,5'-diisopropylsalicylate

cyclic AMP = adenosine cyclic 3':5'-monophosphate

cyclic GMP = guanosine cyclic 3':5'-monophosphate

- DEAE = diethylaminoethyl  
diplosal = salicylsalicylic acid (i.e. salicyl ester of salicylic acid)  
ED<sub>10</sub> = effective dose required to produce 10 lesions to the gastric mucosa  
ED<sub>50</sub> = effective dose required to produce a response in 50 per cent of animals  
EDTA = ethylenediamine tetraacetic acid  
Ent. cell = enterochromaffin cell  
ER = endoplasmic reticulum  
ESR = erythrocyte sedimentation rate  
ETYA = 5,8,11,14-eicosatetraenoic acid  
GAGs = glycosaminoglycans  
G-cell = gastrin cell  
gentisic acid = 2,5-dihydroxybenzoic acid  
GPs = glycoproteins  
GSH = glutathione  
GTP = guanosine triphosphate  
H<sub>1</sub>, H<sub>2</sub> = histamine type 1 and 2 receptors, respectively  
Hb = haemoglobin  
HETE(s) = Hydroxyeicosatetraenoic acids (variously substituted)  
HHT = 12-L-hydroxyheptadecatrienoic acid  
HPETE(s) = hydroperoxyeicosatetraenoic acids (variously substituted)  
HPLC = high-performance (or pressure) liquid chromatography  
IC<sub>50</sub> = inhibitory concentration required to produce 50 per cent reduction in response  
IgG = immunoglobulin G  
log P = logarithm of the partition coefficient between *n*-octanol and an aqueous mixture  
LTs (C<sub>4</sub>, D<sub>4</sub>, E<sub>4</sub>) = leukotriene(s) (C<sub>4</sub>, D<sub>4</sub>, E<sub>4</sub>, respectively)  
MK-447 = 2-aminomethyl-4-*tert*-butyl-6-iodophenol  
MOPS = multisubstrate oxidizing peroxidases  
NDGA = nordihydroguaiaretic acid  
NSAI = non-steroidal anti-inflammatory (drugs)  
O<sub>2</sub><sup>•-</sup> = superoxide ion  
[O]<sub>x</sub><sup>•</sup> = hypothetical oxygen radical species deriving from peroxidation of PGG<sub>2</sub> or HPETEs  
OH<sup>•</sup> = hydroxyl radical  
PAF = platelet aggregating factor = 1-*O*-alkyl-2-acetyl-*sn*-glyceryl-3-phosphorylcholine  
PCO<sub>2</sub> = partial pressure of carbon dioxide  
PGDH = prostaglandin 15-hydroxydehydrogenase  
PO<sub>2</sub> = partial pressure of oxygen  
pyrocatechoic acid = 2,3-dihydroxybenzoic acid  
γ-resorcylic acid = 2,6-dihydroxybenzoic acid  
RNA and DNA = ribonucleic and deoxyribonucleic acids  
SA = salicylic acid (2-hydroxybenzoic acid)  
Sal = salicylate (anion)  
salicylazasulphapyridine = salazapyrin; sulphasalazine; 2-hydroxy-5-[[4-[(2-pyridinylamino)sulphonyl]phenyl]azo]benzoic acid

salol = phenol ester of salicylic acid

salophen = phenetsal = paracetamol ester of salicylic acid

serotonin = 5-hydroxytryptamine

SGOT = serum glutamate-oxaloacetate transaminases

SGPT = serum glutamate-pyruvate transaminases

SLE = systemic lupus erythematosus

SRS-A = slow-reacting substance(s) in anaphylaxis ( $= \text{LTC}_4 + \text{LTD}_4$ )

T-cell = thymus-derived lymphocytes

$\text{TX}(\text{A}_2, \text{B}_2)$  = thromboxanes ( $\text{A}_2, \text{B}_2$ )

UDP = uridine diphosphate

$V_D$  = volume of distribution

# Contents

## Abbreviations and Nomenclature ix

## 1 History and Development of the Salicylates : 1

### Early use of salicylate-containing plants 1

- Hippocratic era 1
- Roman and Greek medicine 1
- Asia and America 2
- European Middle Ages 2
- Nineteenth century 3

### Chemical developments : 3

- Isolation and purification of salicylic acid 3
- Synthesis and commercial development of aspirin (acetylsalicylic acid) 7
- Other salicylates 11

## 2 Occurrence, Properties and Synthetic Developments of the Salicylates 13

### Naturally occurring salicylates 13

### Commercial synthesis and properties of the salicylates 15

- Salicylic and acetylsalicylic acids, their salts and esters 15
- Salicylamide 16
- Salicylate derivatives 17
  - Diffunisal and flufenisal* 18
  - Benorylate* 19
  - Meseclazone* 19

### Experimental drugs 20

- 3-Methylsalicylic acid 20
- Aspirin anhydride 21
- Dihydroxy- and diacetoxybenzoic acids 21
- Salicylazosulphapyridine (sulphasalazine) and 5-aminosalicylic acids 22

Ester pro-drugs	23
Other salicylate derivatives	27

Conclusions	28
-------------	----

### 3 Absorption, Metabolism and Disposition of the Salicylates 32

Introduction	32
--------------	----

Absorption, Metabolism and Distribution	32
---	----

Aspirin, salicylate and their esters	32
Factors influencing absorption	32
Non-enzymic hydrolysis	34
Aspirin esterases and protein acetylation	36
Hydroxylation and conjugation of salicylates	38
Plasma protein binding	41
Factors influencing drug binding to plasma proteins	42
Binding characteristics	42
Binding sites for salicylate on albumin	44
Protein binding in relation to pharmacokinetics	45
Absorption and elimination kinetics	45
Drug formulations	47
Aspirin-Drug interactions	49

Diflunisal	50
Benorylate	51
Salicylamide	53
Salicylazosulphapyridine (sulphasalazine)	53
Salicylsalicylic acid (diplosal, salysal, salsalate)	55
Percutaneous absorption of salicylate esters and other derivatives	55
Experimental pro-drugs	55

#### Analytical Methods 56

Colorimetric and spectrophotometric procedures	56
Spectrofluorimetry	57
Thin-layer chromatography	57
Gas-liquid chromatography	57
High pressure (performance) liquid chromatography	58
Determination of glucuronides and sulphate metabolites	58

### 4 Pharmacological and Biochemical Actions of the Salicylates 67

Introduction	67
--------------	----

Anti-inflammatory effects	69
---------------------------	----

Studies in animal models	69
--------------------------	----

Acute inflammatory models	71
---------------------------	----

<i>Paw oedema assays</i>	71
<i>Pleurisy, air-bleb and sponge-implantation models</i>	73
<i>Actions of salicylates in acute inflammatory models</i>	73
<i>Comparative effects of different drugs</i>	73
<i>Role of mediators of the inflammatory response</i>	75
<i>Structure-activity relationships</i>	78
<i>Chronic adjuvant polyarthritis (rats)</i>	82
<i>Comparative effects of salicylates and other NSAID drugs in adjuvant arthritis</i>	87
<i>Biochemical and cellular responses of salicylates in adjuvant disease</i>	88
<i>Actions of salicylates in other chronic models of inflammation</i>	90
<i>Biochemical effects of salicylates in relation to their anti-inflammatory actions</i>	91
<i>Synthesis and metabolism of prostaglandins, thromboxanes and leukotrienes</i>	91
<i>Effects of salicylates on prostaglandin production</i>	96
<i>Actions of salicylates on 12-HETE and leukotriene production</i>	99
<i>Effects of salicylates on free radical production</i>	100
<i>Early-phase amines and kinins</i>	101
Histamine	102
Serotonin	102
Kinins	103
Lysosomal enzymes	103
<i>Endothelial damage, leucocyte migration and platelet accumulation</i>	106
Platelet aggregation and thrombus formation	106
Mechanisms of inhibition of platelet aggregation by salicylates	107
Comparison of the anti-aggregatory properties of different salicylates: importance of chemical structure	109
Thrombolytic/fibrinolytic activity	111
Chemotaxis of polymorphs and monocytes	112
<i>Displacement of albumin-bound peptides and tryptophan</i>	113
<i>Connective tissue metabolism</i>	113
Metabolism of glucose	115
Production of ATP	115
Synthesis of connective tissue proteoglycans and glycoproteins	118
Anti-proliferative activities	122
<i>Lymphocyte transformation and functions</i>	123
<i>Analgesic activity</i>	123
Introduction	123
Mechanisms of pain responses	124
Comparative effects of salicylates in pain models in animals	124
Mechanisms of analgesia	126
Responses in central and peripheral nerves	126



Prostaglandins	126
Serotonin production in the CNS	127
Actions on nerve membranes and functions	127
Other biochemical changes	129

## Anti-pyresis 130

Comparative efficacy of different salicylates	130
Mode of actions of salicylates	130

# 5 Side-Effects and Toxicology of the Salicylates 148

## Introduction 148

## Gastrointestinal side-effects 151

### Historical 151

### Aspirin as a major cause of bleeding and ulceration 152

### Gastrointestinal side-effects from salicylates in arthritic patients 154

### Assessment of gastrointestinal damage in man 156

#### *Gastroscopy and gastrointestinal blood loss methods* 156

#### *Intragastric cell exfoliation* 159

#### *Gastrointestinal protein loss* 160

#### *Intragastric bleeding* 160

#### *Factors affecting gastrointestinal damage* 161

##### Acidity of the gastric contents 161

##### The presence of food in the stomach 161

##### Dosage and timing of drug ingestion 161

##### Oral versus parenteral effects of salicylates 162

##### Blood group status, race, age and sex 163

##### Exacerbation by alcohol (ethanol) 163

##### Vitamin C (ascorbate) deficiency 164

### Site and pathology of lesions 164

### Studies in laboratory animals 165

#### *Procedures for assessment of gastrointestinal damage* 165

#### *Comparison of the gastro-intestinal damage by different salicylates* 172

#### *Factors influencing gastric ulcerogenicity* 176

##### Alcohol consumption 176

##### Disease psychophysiological stress 176

##### Nutritional status 177

##### Vitamin C status 179

##### Dosage, route and timing of drug administration 180

##### Sex and age 184

##### Particle size of drug 185

##### Physicochemical and structural features of salicylates 185

#### *Comparison of some of the factors influencing gastric mucosal damage by aspirin in man with those in laboratory animals* 187

#### *Intestinal damage* 188

#### *Pathology of salicylate-induced gastrointestinal damage* 189

The gastric mucosa	189
The intestinal mucosa	200
Mechanisms of gastric mucosal damage by salicylates	201
<i>Primary changes</i>	201
Effects of the mucosal barrier	201
Disruption of mucus and mucosal cells	202
Capillary damage	204
Effects of salicylates on mucosal blood flow, acid secretion and $H^+$ ion back diffusion	206
Pepsin and lysosomal mucosal autodigestion	213
Prostaglandin inhibition and mucosal cytoprotection	214
<i>Secondary changes</i>	218
Reduction in mucus	218
Mucosal detoxification	219
Cell turnover and mucosal protein and nucleic acid syntheses	220
<i>Tertiary changes</i>	221
Summary	221
Nephropathy	221
Analgesic abuse syndrome	222
Studies in arthritic patients	225
Pathology	226
Biochemical effects of salicylates	229
Factors influencing drug distribution and actions	229
Prostaglandins, kinins, the renin-angiotensin system and renal functions	231
Renal intermediary metabolism and biosynthesis of macromolecules	232
Hepatotoxicity	233
Clinical evidence	233
Pathology and biochemical changes	235
Hypersensitivity reactions and asthma	236
Aspirin-sensitive asthma	237
Urticaria and angioedema	240
Teratogenesis and pregnancy	241
Miscellaneous side-effects	243
Acute salicylate poisoning	245
Toxic manifestations	245
Central nervous system (CNS) effects	245
Gastrointestinal effects	246
Metabolic effects and acid-base balance	246
Vomiting and electrolyte imbalance	247
Pulmonary oedema	247
Renal damage	247

Dosage	247
Management	248
Conclusions	249

## 6 Therapeutic Uses of the Salicylates 272

Introduction	272
Arthritic conditions	273
Rheumatoid arthritis	273
<i>Aspirin, salicylate and their esters compared with acidic NSAID drugs</i>	275
<i>Salicylazosulphapyridine (sulphasalazine)</i>	278
Other salicylates	278
Osteoarthritis (osteoarthrosis)	279
Miscellaneous	280
Gout	280
Still's disease (juvenile rheumatoid arthritis)	281
Systematic lupus erythematosus (SLE)	281
Rheumatic fever	281
Drug monitoring	281
Interactions with other anti-inflammatory drugs	282
Analgesia	284
Assessment of pain	284
Migraine and headache	284
Acute surgery	286
Postpartum and episiotomy	287
Dysmenorrhoea	288
Cancer	289
Anti-pyresis	289
Thromboembolic conditions	290
Perturbed metabolic states	293
Diabetes mellitus	294
Thyroiditis and thyrotoxicosis	295
Bartter's syndrome	296
Obesity	296
Cystic fibrosis	297
Other possible uses	297
Dermatological conditions	297
Diarrhoea	298
Ductus arteriosus	298
Sickle-cell anaemia	298
Thrombocytic thrombocytopenic purpura	299